266 related articles for article (PubMed ID: 26880977)
1. Vitamin D and the Epithelial to Mesenchymal Transition.
Larriba MJ; García de Herreros A; Muñoz A
Stem Cells Int; 2016; 2016():6213872. PubMed ID: 26880977
[TBL] [Abstract][Full Text] [Related]
2. The transcription factors Snail1 and Snail2 repress vitamin D receptor during colon cancer progression.
Larriba MJ; Bonilla F; Muñoz A
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):106-9. PubMed ID: 20138990
[TBL] [Abstract][Full Text] [Related]
3. 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) Signaling Capacity and the Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer (NSCLC): Implications for Use of 1,25(OH)2D3 in NSCLC Treatment.
Upadhyay SK; Verone A; Shoemaker S; Qin M; Liu S; Campbell M; Hershberger PA
Cancers (Basel); 2013 Nov; 5(4):1504-21. PubMed ID: 24217116
[TBL] [Abstract][Full Text] [Related]
4. MART-10, a less calcemic vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro.
Chiang KC; Chen SC; Yeh CN; Pang JH; Shen SC; Hsu JT; Liu YY; Chen LW; Kuo SF; Takano M; Kittaka A; Sun CC; Juang HH; Chen TC
J Steroid Biochem Mol Biol; 2014 Jan; 139():54-60. PubMed ID: 24125734
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D inhibits the epithelial-mesenchymal transition by a negative feedback regulation of TGF-β activity.
Ricca C; Aillon A; Viano M; Bergandi L; Aldieri E; Silvagno F
J Steroid Biochem Mol Biol; 2019 Mar; 187():97-105. PubMed ID: 30465855
[TBL] [Abstract][Full Text] [Related]
6. Effects of 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells.
González-Sancho JM; Larriba MJ; Ordóñez-Morán P; Pálmer HG; Muñoz A
Anticancer Res; 2006; 26(4A):2669-81. PubMed ID: 16886677
[TBL] [Abstract][Full Text] [Related]
7. Singly dehydroxylated A-ring analogues of 19-nor-1alpha,25-dihydroxyvitamin D3 and 19-nor-22-oxa-1alpha,25-dihydroxyvitamin D3: novel vitamin D3 analogues with potent transcriptional activity but extremely low affinity for vitamin D receptor.
Okano T; Nakagawa K; Tsugawa N; Ozono K; Kubodera N; Osawa A; Terada M; Mikami K
Biol Pharm Bull; 1998 Dec; 21(12):1300-5. PubMed ID: 9881643
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of 1α,25-dihydroxyvitamin D3-dependent chromatin accessibility of early vitamin D receptor target genes.
Seuter S; Pehkonen P; Heikkinen S; Carlberg C
Biochim Biophys Acta; 2013 Dec; 1829(12):1266-75. PubMed ID: 24185200
[TBL] [Abstract][Full Text] [Related]
9. The vitamin D hormone and its nuclear receptor: molecular actions and disease states.
Haussler MR; Haussler CA; Jurutka PW; Thompson PD; Hsieh JC; Remus LS; Selznick SH; Whitfield GK
J Endocrinol; 1997 Sep; 154 Suppl():S57-73. PubMed ID: 9379138
[TBL] [Abstract][Full Text] [Related]
10. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
11. The vitamin D receptor in the proximal renal tubule is a key regulator of serum 1α,25-dihydroxyvitamin D₃.
Wang Y; Zhu J; DeLuca HF
Am J Physiol Endocrinol Metab; 2015 Feb; 308(3):E201-5. PubMed ID: 25425001
[TBL] [Abstract][Full Text] [Related]
12. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.
Akutsu N; Lin R; Bastien Y; Bestawros A; Enepekides DJ; Black MJ; White JH
Mol Endocrinol; 2001 Jul; 15(7):1127-39. PubMed ID: 11435613
[TBL] [Abstract][Full Text] [Related]
13. 1α,25-Dihydroxyvitamin D
Ishizawa M; Akagi D; Yamamoto J; Makishima M
J Steroid Biochem Mol Biol; 2017 Sep; 172():55-61. PubMed ID: 28578001
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of 1α-hydroxylase and vitamin D receptor in human articular chondrocytes.
Hansen AK; Figenschau Y; Zubiaurre-Martinez I
BMC Musculoskelet Disord; 2017 Nov; 18(1):432. PubMed ID: 29110708
[TBL] [Abstract][Full Text] [Related]
15. Potent vitamin D3 analogs: their abilities to enhance transactivation and to bind to the vitamin D3 response element.
Imai Y; Pike JW; Koeffler HP
Leuk Res; 1995 Mar; 19(3):147-58. PubMed ID: 7700077
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
17. 1,25(OH)2D3 treatment attenuates high glucose‑induced peritoneal epithelial to mesenchymal transition in mice.
Yang L; Fan Y; Zhang X; Huang W; Ma J
Mol Med Rep; 2017 Oct; 16(4):3817-3824. PubMed ID: 28765896
[TBL] [Abstract][Full Text] [Related]
18. Snail2 cooperates with Snail1 in the repression of vitamin D receptor in colon cancer.
Larriba MJ; Martín-Villar E; García JM; Pereira F; Peña C; de Herreros AG; Bonilla F; Muñoz A
Carcinogenesis; 2009 Aug; 30(8):1459-68. PubMed ID: 19502595
[TBL] [Abstract][Full Text] [Related]
19. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor.
Dunlop TW; Väisänen S; Frank C; Molnár F; Sinkkonen L; Carlberg C
J Mol Biol; 2005 Jun; 349(2):248-60. PubMed ID: 15890193
[TBL] [Abstract][Full Text] [Related]
20. Metabolic stability of 3-epi-1α,25-dihydroxyvitamin D3 over 1 α 25-dihydroxyvitamin D3: metabolism and molecular docking studies using rat CYP24A1.
Rhieu SY; Annalora AJ; Wang G; Flarakos CC; Gathungu RM; Vouros P; Sigüeiro R; Mouriño A; Schuster I; Palmore GT; Reddy GS
J Cell Biochem; 2013 Oct; 114(10):2293-305. PubMed ID: 23606409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
